NVAX - Novavax, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.29
+0.02 (+1.57%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.27
Open1.27
Bid1.21 x 3000
Ask1.36 x 1800
Day's Range1.26 - 1.30
52 Week Range0.96 - 2.75
Volume2,342,829
Avg. Volume4,177,045
Market Cap493.544M
Beta3.19
PE Ratio (TTM)N/A
EPS (TTM)-0.60
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.86
Trade prices are not sourced from all markets
  • Analyzing Novavax’s Financial Performance
    Market Realist17 hours ago

    Analyzing Novavax’s Financial Performance

    Novavax (NVAX) generated revenue of $10.77 million in the second quarter compared to $6.73 million in the comparable period in 2017. The increase in the company’s revenue resulted from a $2 million increase in the Bill and Melinda Gates Foundation grant revenue due to higher enrolment in Novavax’s Prepare trial and an additional $2 million from increased activities from Novavax AB. The general and administrative expenses incurred by Novavax decreased from $8.94 million in the second quarter of 2017 to $8.22 million in the second quarter of 2018.

  • Gauging Analysts’ Expectations for Novavax and Peers in August
    Market Realist17 hours ago

    Gauging Analysts’ Expectations for Novavax and Peers in August

    Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing to market recombinant nanoparticle vaccines and adjuvants. Novavax makes use of its proprietary recombinant nanoparticle vaccine technology and saponin-based adjuvant technology to develop vaccine candidates that target different infectious diseases, such as the respiratory syncytial virus and influenza. Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation (or BMGF), which is the current source of its revenue.

  • 5 Promising Vaccines in Development -- and the Stocks Poised to Profit From Them
    Motley Fool2 days ago

    5 Promising Vaccines in Development -- and the Stocks Poised to Profit From Them

    Nearly $5 billion in combined annual sales could be on the way from these top vaccines in development.

  • Why Novavax, Inc. Shares Are Soaring Today
    Motley Fool8 days ago

    Why Novavax, Inc. Shares Are Soaring Today

    The clinical-stage biotech provided good news for two key vaccines in its pipeline.

  • ACCESSWIRE8 days ago

    Today's Research Reports on Trending Tickers: Novavax and INSYS Therapeutics

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / U.S. equities were mixed on Wednesday as a result of disappointing corporate earnings combined with the latest trade news. The Dow Jones Industrial Average ...

  • Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates
    Zacks8 days ago

    Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates

    Novavax (NVAX) delivered earnings and revenue surprises of 0.00% and 4.85%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press8 days ago

    Novavax: 2Q Earnings Snapshot

    On a per-share basis, the Gaithersburg, Maryland-based company said it had a loss of 12 cents. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • GlobeNewswire9 days ago

    Novavax Reports Second Quarter 2018 Financial Results

    Novavax Delivers on Key Milestones Supporting its 2018 Objectives. Company to Host Conference Call Today at 4:30 pm ET. GAITHERSBURG, Md., Aug. 08, 2018-- Novavax, Inc. today announced its financial results ...

  • ACCESSWIRE9 days ago

    Novavax, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Novavax, Inc. (NASDAQ: NVAX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 PM Eastern Time. To ...

  • GlobeNewswire16 days ago

    Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 8, 2018

    GAITHERSBURG, Md., Aug. 01, 2018-- Novavax, Inc. today announced it will report its second quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, August ...

  • How to Invest in Clinical-Stage Biotechs Without Losing Money
    Motley Fool20 days ago

    How to Invest in Clinical-Stage Biotechs Without Losing Money

    Clinical-stage biotechs can wreak havoc on your portfolio. Here's one approach that can limit the potential damage while still allowing you to take a long-term approach to capital appreciation.

  • GlobeNewswire22 days ago

    Consolidated Research: 2018 Summary Expectations for At Home Group, Royal Bank Of Canada, Curis, Novavax, HNI, and Freshpet — Fundamental Analysis, Key Performance Indications

    NEW YORK, July 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of At ...

  • Investopedia25 days ago

    Top 3 Healthcare Penny Stocks for 2018

    The healthcare industry can be precarious for stocks of large companies, much less penny stocks. Of course, small-cap healthcare companies can be nudged out of the market by big competitors, and they can simply become unable to service debt when products and services don't sell quickly enough. None of these are new companies – they have made progress in developing products and finding the marketing outlets that are needed to sustain them.

  • Better Buy: Novavax, Inc. vs. Pfizer
    Motley Fool29 days ago

    Better Buy: Novavax, Inc. vs. Pfizer

    Novavax and Pfizer have been chronic underachievers, but their stocks may soon perk up. Here's a look at which stock is the better buy right now.

  • Why Novavax Stock Buckled in June
    Motley Foollast month

    Why Novavax Stock Buckled in June

    Novavax's stock got blasted by geopolitical headwinds last month, but that doesn't mean it's now a bargain.

  • ACCESSWIRElast month

    Free Technical Reports on Novavax and Three Additional Biotech Equities

    WallStEquities.com has initiated research reports on the following Biotechnology stocks: Nabriva Therapeutics PLC (NASDAQ: NBRV), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Novavax Inc. (NASDAQ: NVAX), and Novo Nordisk A/S (NYSE: NVO). All you have to do is sign up today for this free limited time offer by clicking the link below.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Novavax and Nektar Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 25, 2018 / U.S. markets were mixed Friday, with the Dow snapping an eight day losing streak as energy shares rallied. However, major indexes experienced weekly losses on ...

  • 3 Stocks That Could Make You Rich
    Motley Fool2 months ago

    3 Stocks That Could Make You Rich

    The road to riches might be paved with buying stocks like these.

  • Are These 2 Dark Horse Vaccine Makers Worth the Risk?
    Motley Fool2 months ago

    Are These 2 Dark Horse Vaccine Makers Worth the Risk?

    A new industry report suggests that Novavax and Inovio Pharmaceuticals might be grossly undervalued right now.

  • Why Novavax Sees a Huge Opportunity in Its Influenza Vaccine
    Market Realist2 months ago

    Why Novavax Sees a Huge Opportunity in Its Influenza Vaccine

    Novavax (NVAX) expects the seasonal influenza vaccine market in the world’s top seven markets to grow from ~$3.2 billion in the 2012–2013 season to $5.3 billion by the 2021–2022 season. Influenza is an infectious disease that causes illness in humans, ranging from mild to life-threatening symptoms or death. Largely in part due to infection by unique strains of influenza for which most people have not developed protective antibodies, serious illness occurs in susceptible populations (such as the elderly and very young) as well as the general population.

  • Novavax’s Cash Flow Trends
    Market Realist2 months ago

    Novavax’s Cash Flow Trends

    Novavax (NVAX) completed a public offering of ~34.9 million shares of its common stock in April. Through this offering, the company raised ~$54 million. In the first quarter, Novavax sold 15.7 million of its common shares, raising $32.3 million in net proceeds. Its number of outstanding shares is expected to rise to ~400 million from ~262 million between fiscal 2015 and fiscal 2019.

  • Analyzing Novavax’s Financial Performance
    Market Realist2 months ago

    Analyzing Novavax’s Financial Performance

    Novavax (NVAX) generates revenue in the form of grants from the Bill and Melinda Gates Foundation (or BMGF) for the development of its RSV F (respiratory syncytial virus fusion protein) vaccine for infants via maternal immunization. During the first quarter of fiscal 2018, the company’s revenue rose YoY (year-over-year) to $9.7 million from $5.7 million. The BMGF awarded an $89.1 million grant to Novavax in 2015, of which the company has recognized $51 million so far.

  • Analyzing Novavax’s Clinical Vaccine Programs
    Market Realist2 months ago

    Analyzing Novavax’s Clinical Vaccine Programs

    In addition to developing RSV (respiratory syncytial virus) and influenza vaccines, Novavax (NVAX) is also developing immune-stimulating saponin-based adjuvants through its Swedish subsidiary, Novavax AB. Its lead adjuvant, Matrix-M, has been shown to enhance immune response and has been well tolerated in multiple clinical trials.

  • How Much Upside Analysts See In Novavax Stock
    Market Realist2 months ago

    How Much Upside Analysts See In Novavax Stock

    Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing recombinant nanoparticle vaccines and adjuvants to market. Of the eight analysts covering Novavax, four have recommended “buy” or a higher rating, three have recommended “hold,” and one has recommended “sell.” Their mean rating for the stock is 2.4, and their target price is $3.93, implying a 144% upside based on its June 13 closing price of $1.61. Of the 20 analysts covering Merck (MRK), 15 have recommended “buy” or a higher rating, and five have recommended “hold.” Their mean rating for the stock is 2, and their target price is $69.02.

  • GlobeNewswire2 months ago

    New England Journal of Medicine Publishes Novavax' NanoFlu Clinical Trial Data

    NanoFlu TM  Phase 1/2 trial data published in a peer-reviewed letter to the editor in  The New England Journal of Medicine NanoFlu demonstrates significantly improved immune responses against a panel of ...